Streetbeat News

Revenues

FN

Fabrinet (NYSE:FN) has significantly outperformed the market over the past decade, with an annualized return of 30.57%. A $100 investment in Fabrinet 10 years ago would now be worth $1,428.23, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:30 pm

DKNG

FOX

FOXA

The 2024 World Series between the Los Angeles Dodgers and New York Yankees could benefit Fox Corporation due to high viewership potential. The series, airing exclusively on Fox, features the two most valuable MLB teams, which could lead to increased ratings and advertising revenue for Fox. DraftKings provides betting odds favoring the Dodgers.

Portfolio Pulse from Chris Katje

October 24, 2024 | 3:14 pm

VZ

Verizon Communications Inc. (NYSE:VZ) shares fell 2.66% to $41.72 after reporting mixed Q3 results. Revenue was flat at $33.33 billion, missing expectations, but EPS slightly beat estimates. Wireless service revenue grew by 2.7%, and broadband subscribers increased by 16%. However, net income dropped due to severance costs.

Portfolio Pulse from Henry Khederian

October 24, 2024 | 3:10 pm

TR

Tootsie Roll Industries reported a decrease in Q3 earnings per share to $0.46 from $0.48 year-over-year, and a decline in sales to $223.89 million from $248.34 million.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 3:08 pm

WSO

Analysts have recently evaluated Watsco (NYSE:WSO), providing a range of ratings from somewhat bullish to indifferent. The average 12-month price target has increased by 4.35% to $509.25. Watsco's financial metrics, such as revenue growth and net margin, indicate strong performance, although revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

JNJ

The article provides a comparative analysis of Johnson & Johnson (JNJ) against its competitors in the Pharmaceuticals industry. JNJ shows potential undervaluation with lower PE, PB, and PS ratios compared to industry averages. However, it underperforms in ROE, EBITDA, gross profit, and revenue growth, indicating potential operational inefficiencies. Despite this, JNJ maintains a strong financial position with a lower debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:01 pm

T

AT&T (NYSE:T) has received mixed analyst ratings over the past three months, with a trend towards more bullish perspectives. Analysts have adjusted their 12-month price targets upwards, with an average target of $24.14, reflecting a 6.3% increase from the previous average. Despite revenue challenges, AT&T's net margin and return on equity are strong, though its return on assets and debt management indicate potential risks.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:00 pm

MU

The article evaluates Micron Technology (NASDAQ:MU) against its peers in the Semiconductors & Semiconductor Equipment industry, focusing on financial metrics, market position, and growth potential. Micron's high P/E ratio suggests overvaluation, while its low P/B and P/S ratios indicate potential undervaluation. Despite strong revenue growth, Micron lags in ROE, EBITDA, and gross profit compared to industry averages.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:00 pm

IMCR

In the past three months, 9 analysts have provided mixed evaluations for Immunocore Holdings (NASDAQ:IMCR), with a range of ratings from bullish to bearish. The average 12-month price target has decreased by 12.22% to $79.11. Analysts have adjusted their ratings and price targets, reflecting their views on the company's current state. Immunocore Holdings, a biotechnology company, has shown a 26.18% revenue growth rate but lags behind industry peers. The company maintains strong financial health with efficient cost management and a balanced debt approach.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:00 pm

FBP

Analysts have mixed opinions on First BanCorp (NYSE:FBP), with recent ratings showing a neutral stance. The average 12-month price target is $21.25, slightly down from previous estimates. Despite revenue challenges, First BanCorp maintains strong financial health with high net margins and efficient asset use.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 3:00 pm